Last reviewed · How we verify
budesonode bid + terbutaline 'as needed'
Budesonide is a corticosteroid that reduces inflammation, while terbutaline is a beta-2 adrenergic receptor agonist that relaxes airway muscles.
Budesonide is a corticosteroid that reduces inflammation, while terbutaline is a beta-2 adrenergic receptor agonist that relaxes airway muscles. Used for Asthma maintenance and control, Chronic obstructive pulmonary disease (COPD) maintenance and control.
At a glance
| Generic name | budesonode bid + terbutaline 'as needed' |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Corticosteroid + Beta-2 adrenergic receptor agonist |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Budesonide works by inhibiting the production of inflammatory mediators, thereby reducing inflammation in the airways. Terbutaline, on the other hand, stimulates the beta-2 adrenergic receptors, leading to bronchodilation and relaxation of airway smooth muscles.
Approved indications
- Asthma maintenance and control
- Chronic obstructive pulmonary disease (COPD) maintenance and control
Common side effects
- Headache
- Nausea
- Tremors
- Muscle cramps
- Cough
- Dysphonia
- Oral candidiasis
- Hypokalemia
- Palpitations
- Tachycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- budesonode bid + terbutaline 'as needed' CI brief — competitive landscape report
- budesonode bid + terbutaline 'as needed' updates RSS · CI watch RSS
- AstraZeneca portfolio CI